XERIS BIOPH.HOL. DL-0001
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and… Read more
XERIS BIOPH.HOL. DL-0001 (2B30) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, XERIS BIOPH.HOL. DL-0001 (2B30) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
XERIS BIOPH.HOL. DL-0001 - Net Assets Trend (None–None)
This chart illustrates how XERIS BIOPH.HOL. DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for XERIS BIOPH.HOL. DL-0001 (None–None)
The table below shows the annual net assets of XERIS BIOPH.HOL. DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to XERIS BIOPH.HOL. DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
XERIS BIOPH.HOL. DL-0001 Competitors by Market Cap
The table below lists competitors of XERIS BIOPH.HOL. DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Isracard Ltd
OTCGREY:ISCDF
|
$759.18 Million |
|
Anhui Huaheng Biotechnology Co. Ltd. A
SHG:688639
|
$759.43 Million |
|
Jiangsu Zhengdan Chemical Industry Co Ltd
SHE:300641
|
$759.51 Million |
|
HJ ShipBuilding & Construction Co Ltd
KO:097230
|
$759.55 Million |
|
Epoxy Base Electronic Material Corp Ltd
SHG:603002
|
$758.72 Million |
|
Zhejiang Jiecang Linear Motion Technology Co Ltd
SHG:603583
|
$758.39 Million |
|
Tamilnad Mercantile Bank Limited
NSE:TMB
|
$758.16 Million |
|
Actions Technology Co Ltd
SHG:688049
|
$758.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in XERIS BIOPH.HOL. DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares XERIS BIOPH.HOL. DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently XERIS BIOPH.HOL. DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares XERIS BIOPH.HOL. DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| XERIS BIOPH.HOL. DL-0001 (2B30) | €- | N/A | N/A | $759.00 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |